Compared with cisplatin, the biparatopic anti-EGFR NDC enables efficient internalization into EGFR-positive cancer cells due to 4–5 fold higher tumor accumulation, thereby enhancing tumor-specific drug delivery while minimizing systemic distribution. Here, EGFR is linked to cancer.